A Pilot Study of 68Ga-MZHER2 Affibody in HER2-positive Gastric Cancer Patients

Conclusions: We produced clinical grade 68Ga-NOTA-MAL-MZHER2 agent for HER2 targeting PET imaging. And a pilot PET/CT imaging demonstrated a favorable bio-distribution, safety profile. Compared with 18F-FDG, it showed better detection capability of bone metastases from HER2-positive gastric cancer. And 68Ga-NOTA-MAL-MZHER2 holds a great potential for noninvasive detection of metastatic bone lesions in patients with HER2-positive gastric cancer. Key Words: 68Ga-NOTA-MAL-MZHER2, PET/CT, Gastric cancer, metastatic bone lesions, HER2 Finical Support: the National Key Research and Development Program of China (No. 2017YFC1308900), Beijing Nova program (Z171100001117020). Ethical approval: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients. The clinical study was approved by the Ethics Committee of the Beijing Cancer Hospital (Ethics Approval License: 2018KT61).Figure1. PET/CT images in a 54 y female patient with HER2-positive primary gastric cancer and multiple bone metastases in the whole body.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Preclinical Probes for Oncology II Source Type: research